This week, Frost & Sullivan—a global researching and consulting organization—together with Rani Therapeutics, a drug manufacturer developing an approach to the oral delivery of large-molecule drugs, announced the results of a combined research study. The study suggested that biosimilar developers could gain market share from brand-name biologics by developing the biosimilars in oral form.
This week, Frost & Sullivan—a global researching and consulting organization—together with Rani Therapeutics, a drug manufacturer developing an approach to the oral delivery of large-molecule drugs, announced the results of a combined research study. The study suggested that biosimilar developers could gain market share from brand-name biologics by developing the biosimilars in oral form.
The research included a survey of more than 500 patients, and more than 100 physicians, including rheumatologists and gastroenterologists. The survey found that 88% of patients and 86% of rheumatologists and gastroenterologists would likely switch from adalimumab (Humira) injections to once-daily pills if an effective oral alternative existed.
Additionally, the results of the study found that such an oral drug could increase patient compliance with treatment. This factor is especially notable in light of the survey’s finding that 62% of patients and 86% of physicians reported that patients either skip or consistently fail to inject the drug as prescribed.
“Humira is the number 1 selling drug in the world, yet this research shows that its sales and AbbVie’s revenues could potentially be threatened by oral adalimumab because of fear of needles and the associated lack of patient compliance. Combine those challenges with patent expiration and the increasing threat of biosimilars, which are forecast to hit the market in the coming years, and it’s the perfect storm,” said Mir Imran, chairman and CEO of Rani Therapeutics, in a statement.
However, the companies did not address the key question of whether regulatory bodies like the FDA or the European Medicines Agency would approve such an orally administered drug as a biosimilar of an injectable or infusible reference product, as such a drug would not be similar in its route of administration, and challenges with interchangeability (and therefore pharmacy-level substitution for the reference product) would be likely.
Rani Therapeutics is not the first drug maker to see the value in an orally delivered biologic, however. Just last month, Protalix BioTherapeutics, Inc, an Israel-based drug manufacturer, announced positive results from a phase 2 clinical trial for its own novel, orally administered anti-tumor necrosis factor (anti-TNF) drug, OPRX-106, for the treatment of inflammatory bowel disease.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.